Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Physiol
2012 May 15;59010:2519-28. doi: 10.1113/jphysiol.2012.230201.
Show Gene links
Show Anatomy links
Riluzole blocks human muscle acetylcholine receptors.
Deflorio C
,
Palma E
,
Conti L
,
Roseti C
,
Manteca A
,
Giacomelli E
,
Catalano M
,
Limatola C
,
Inghilleri M
,
Grassi F
.
???displayArticle.abstract???
Riluzole, the only drug available against amyotrophic lateral sclerosis (ALS), has recently been shown to block muscle ACh receptors (AChRs), raising concerns about possible negative side-effects on neuromuscular transmission in treated patients. In this work we studied riluzole's impact on the function of muscle AChRs in vitro and on neuromuscular transmission in ALS patients, using electrophysiological techniques. Human recombinant AChRs composed of α(1)β(1)δ subunits plus the γ or ε subunit (γ- or ε-AChR) were expressed in HEK cells or Xenopus oocytes. In both preparations, riluzole at 0.5 μm, a clinically relevant concentration, reversibly reduced the amplitude and accelerated the decay of ACh-evoked current if applied before coapplication with ACh. The action on γ-AChRs was more potent and faster than on ε-AChRs. In HEK outside-out patches, riluzole-induced block of macroscopic ACh-evoked current gradually developed during the initial milliseconds of ACh presence. Single channel recordings in HEK cells and in human myotubes from ALS patients showed that riluzole prolongs channel closed time, but has no effect on channel conductance and open duration. Finally, compound muscle action potentials (CMAPs) evoked by nerve stimulation in ALS patients remained unaltered after a 1 week suspension of riluzole treatment. These data indicate that riluzole, while apparently safe with regard to synaptic transmission, may affect the function of AChRs expressed in denervated muscle fibres of ALS patients, with biological consequences that remain to be investigated.
Bandi,
Autocrine activation of nicotinic acetylcholine receptors contributes to Ca2+ spikes in mouse myotubes during myogenesis.
2005, Pubmed
Bandi,
Autocrine activation of nicotinic acetylcholine receptors contributes to Ca2+ spikes in mouse myotubes during myogenesis.
2005,
Pubmed
Bellingham,
A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
2011,
Pubmed
Bouzat,
Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone. Possible allosteric mechanism of channel blockade.
1996,
Pubmed
Chandu,
Quantitative estimation of riluzole in human plasma by LC-ESI-MS/MS and its application to a bioequivalence study.
2010,
Pubmed
Colquhoun,
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
1998,
Pubmed
Connold,
Temporary loss of activity prevents the increase of motor unit size in partially denervated rat soleus muscles.
1991,
Pubmed
Dadon-Nachum,
The "dying-back" phenomenon of motor neurons in ALS.
2011,
Pubmed
Di Angelantonio,
Adenosine A2A receptor induces protein kinase A-dependent functional modulation of human (alpha)3(beta)4 nicotinic receptor.
2011,
Pubmed
Di Castro,
Pathogenic point mutations in a transmembrane domain of the epsilon subunit increase the Ca2+ permeability of the human endplate ACh receptor.
2007,
Pubmed
Eisen,
Clinical neurophysiology of ALS.
2001,
Pubmed
Forman,
A hydrophobic photolabel inhibits nicotinic acetylcholine receptors via open-channel block following a slow step.
1999,
Pubmed
Fucile,
The human adult subtype ACh receptor channel has high Ca2+ permeability and predisposes to endplate Ca2+ overloading.
2006,
Pubmed
García-Colunga,
Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).
1997,
Pubmed
,
Xenbase
Grassi,
5-hydroxytryptamine blocks the fetal more potently than the adult mouse muscle acetylcholine receptor.
1999,
Pubmed
Harper,
Treatment of slow-channel congenital myasthenic syndrome with fluoxetine.
2003,
Pubmed
KATZ,
FURTHER OBSERVATIONS ON THE DISTRIBUTION OF ACTYLCHOLINE-REACTIVE SITES IN SKELETAL MUSCLE.
1964,
Pubmed
KRNJEVIC,
THE RELEASE OF ACETYLCHOLINE FROM THE DENERVATED RAT DIAPHRAGM.
1964,
Pubmed
Krause,
Activation of nicotinic acetylcholine receptors increases the rate of fusion of cultured human myoblasts.
1995,
Pubmed
Le Liboux,
A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers.
1999,
Pubmed
Liu,
Essential roles of the acetylcholine receptor gamma-subunit in neuromuscular synaptic patterning.
2008,
Pubmed
Miledi,
Microtransplantation of neurotransmitter receptors from cells to Xenopus oocyte membranes: new procedure for ion channel studies.
2006,
Pubmed
,
Xenbase
Mohammadi,
Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels.
2002,
Pubmed
Moriconi,
Mechanism of verapamil action on wild-type and slow-channel mutant human muscle acetylcholine receptor.
2010,
Pubmed
Musarò,
State of the art and the dark side of amyotrophic lateral sclerosis.
2010,
Pubmed
Neher,
Local anaesthetics transiently block currents through single acetylcholine-receptor channels.
1978,
Pubmed
Noh,
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
2000,
Pubmed
Oppenheim,
Reduction of neuromuscular activity is required for the rescue of motoneurons from naturally occurring cell death by nicotinic-blocking agents.
2000,
Pubmed
Palma,
Physiological characterization of human muscle acetylcholine receptors from ALS patients.
2011,
Pubmed
,
Xenbase
Palma,
Expression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy.
2002,
Pubmed
,
Xenbase
Pestronk,
Motor nerve terminal outgrowth and acetylcholine receptors: inhibition of terminal outgrowth by alpha-bungarotoxin and anti-acetylcholine receptor antibody.
1985,
Pubmed
Spitzmaul,
The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms.
2009,
Pubmed
Steinbach,
Antagonist and partial agonist actions of d-tubocurarine at mammalian muscle acetylcholine receptors.
1995,
Pubmed
Terrado,
Motoneuron survival is enhanced in the absence of neuromuscular junction formation in embryos.
2001,
Pubmed
Witzemann,
Neural factors regulate AChR subunit mRNAs at rat neuromuscular synapses.
1991,
Pubmed
Yampolsky,
AChR channel conversion and AChR-adjusted neuronal survival during embryonic development.
2008,
Pubmed
Yampolsky,
Differential muscle-driven synaptic remodeling in the neuromuscular junction after denervation.
2010,
Pubmed
